Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 701 - 750 out of 111,695

Document Document Title
WO/2015/181094A1
The present invention relates to the therapeutic use of derivatives of 1-(2-fluorobiphenyl-4-yl)-cyclopropanecarboxylic acid for improving the cognitive capacity of patients with intellectual disabilities, an IQ of less than 85, diagnose...  
WO/2015/184105A1
The present invention features methods for stimulating clearance of misfolded or aggregated proteins or peptides in microglia or neurons, and treating neurodegenerative diseases associated with such pathology in brain by selectively inhi...  
WO/2015/180342A1
The present invention provides a deuterium substituted 1-[2-(2,4-dimethyl-thiophenyl)-phenyl] piperazine compound with a structure represented by formula (I) or a derivative thereof, a pharmaceutical composition containing the compound o...  
WO/2015/184003A1
Methods for the safe administration of imidazole or imidazolium compounds, and conditions that may be treated by these methods, are described herein.  
WO/2015/180485A1
The present invention relates to an amantadine nitrate compound having a neuroprotective effect and a preparation and a medical use thereof. The compound has the structure of the general formula (I). The compound has multiple mechanisms ...  
WO/2015/184279A1
A method is provided for treating a Mendelian disorder of the epigenetic machinery (e.g., Kabuki syndrome) in a subject in need thereof. In particular, the method comprises administering to the subject a ketogenic composition in an amoun...  
WO/2015/183673A1
A TARP ϒ8 dependant AMPA receptor antagonist of the formula: wherein X is CH or N; A is; and R1 is as defined herein; its pharmaceutically acceptable salts, uses, and methods for its preparation are described.  
WO/2015/181567A1
According to the invention there is provided N,N-bis-2-mercaptoethyl isophthalamide, or a pharmaceutically acceptable salt or derivative thereof, for use in the therapeutic treatment of a neurodegenerative disorder, such as Alzheimer's d...  
WO/2015/180582A1
Provided are a β crystalline form of aripiprazole hemiethanolate, a preparation method thereof and the use for preparing a I crystal form of aripiprazole with a low hygroscopicity. The preparation method for the β and I crystal forms o...  
WO/2015/182232A1
The purpose of the present invention is to provide a novel anti hallucination drug whereby hallucination symptoms can be suppressed, treated or prevented. The anti hallucination drug comprises a crude drug derived from a plant belonging ...  
WO/2015/181061A1
The invention relates to compounds of formula (I) wherein.....C.....is -CH2- or -CH2-CH2-; X is -NH-, -C(0)NH- or -NHC(0)NH-; Ar is phenyl or a 5 or 6-membered heteroaryl group containing one or two N atoms; R1 is halogen, lower alkyl, l...  
WO/2015/181336A1
The invention relates to a compound comprising the following general formula (1) for use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation: (1) wherein each of R1, R 2 and R 3 are...  
WO/2015/182723A1
 Provided are a novel pyrrolidine compound having melanocorin receptor agonist activity, a pharmacologically acceptable salt thereof, and pharmaceutical applications thereof. The present invention pertains to a pyrrolidine derivative r...  
WO/2015/181337A1
The invention relates to a compound comprising the following general formula (1) and said compound for use as a medicament, in particular for use in the treatment psychiatric or neurological disorders and inflammation, in particular neur...  
WO/2015/179360A1
The present invention provides pharmaceutical compositions for treating neuromyelitis optica (NMO) comprising a therapeutically effective amount of loop C sequence-containing peptide of aquaporin-4 (AQP4) water channel, or a therapeutica...  
WO/2015/178020A1
The present invention relates to novel salts of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy }methyl)piperidin-1-yl]methyl}tetrahydro-2H-pyran-4-carboxyl ic acid. More particularly, the invention relates to salt forms (HC...  
WO/2015/178507A1
A composition for enhancement of ability to concentrate and method of improving ability to concentrate using alanylglutamine or a salt of alanylglutamine as an active ingredient.  
WO/2015/179492A1
Methods for preparing nucleic acid nanoparticles having a controllable shape and their use for delivering nucleic acids to a subject in need of treatment of a neurological disease are disclosed.  
WO/2015/179559A3
Provided herein are pyrazole compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of one or more of MAGL, ABHD6, and FAAH. Furthermore, the subject compounds...  
WO/2015/178414A1
 Provided is a method for monomerizing an MMP-7 aggregate. An MMP-7 monomerization method comprising treating an MMP-7 aggregate with a buffer solution including a low concentration of a monovalent cation chloride (such as sodium chlor...  
WO/2015/179867A1
The present invention provides a dendritic cell-based vaccine against a-synuclein, antibodies against a-synuclein, and methods of treating, preventing, and/or vaccinating against Parkinson's Disease (PD). In one aspect, the present inven...  
WO/2015/179559A2
Provided herein are pyrazole compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of one or more of MAGL, ABHD6, and FAAH. Furthermore, the subject compounds...  
WO/2015/176167A1
A method of using Argon gas for treating a condition associated with mu opioid receptors and/or the vesicular monoamine transporter activity in a mammal, condition selected from: anxiety, nervousness, tension, jumpiness, excitability, re...  
WO/2015/177435A1
The invention relates to a drug combination including xenon gas and at least one antioxidant, in liquid or solid form, for use in treating, slowing, or preventing neurological damage following a neurodegenerative disease in a human being...  
WO/2015/177688A1
Compounds of the general formula (I), wherein one of X1 and X2 represents N, and the other one of X1 and X2 represents -C(CH3), A represents unsubstituted or substituted 5-, 6-or 10-membered aryl or heteroaryl, n is 0 or 1 and B is a bic...  
WO/2015/178404A1
The present invention addresses the problem of discovering a carotenoid compound exhibiting excellent water solubility. Provided is a carotenoid derivative represented by general formula (I) [in general formula (I): X represents a carbon...  
WO/2015/179258A2
The present invention provides a method of administering a therapeutic agent directly to the brain parenchym through a compromised region of the blood-brain barrier in a subject having a brain disorder, that involves first disrupting the...  
WO/2015/179258A3
The present invention provides a method of administering a therapeutic agent directly to the brain parenchym through a compromised region of the blood-brain barrier in a subject having a brain disorder, that involves first disrupting the...  
WO/2015/176801A1
The invention relates to transdermal therapeutic systems (TTS) containing lavender oil as active substance and to their use in the prevention and/or treatment of excitation, sleep disturbances, anxiety and nervousness, in particular of e...  
WO/2015/177110A1
The present invention is concerned with indolin-2-one and l,3-dihydro-pyrrolo[3,2-c]pyridin-2-one derivatives of general formula (I) wherein Ar1 is phenyl, pyridinyl or pyrimidinyl; Ar2 is a 5 or 6 membered heteroaryl group, containing 2...  
WO/2015/179125A1
Methods are disclosed for treating multiple sclerosis comprising administering an agent that reduces expression and/or activity of Allograft inflammatory factor- 1 (Aif-1) in a subject and for screening for such agents.  
WO/2015/176800A1
The invention relates to a transdermal therapeutic system in the form of a plaster, for administering the active agent amitriptyline. Said system has a back layer which is impermeable to the active agent, an active agent reservoir which ...  
WO/2015/175974A1
Provided herein are methods and composition for the treatment for macrophage-related disorders, for example through the use of biomarkers for selection of responders and treatment monitoring.  
WO/2015/176069A3
Analogs of (4aS,6R,8aS)- 5,6,9,10,11,12- hexahydro- 3-methoxy- 11-methyl- 4aH- [1]benzofuro[3a,3,2-ef] [2] benzazepin- 6-ol of the formula: wherein R1 is carbamate, carbonate or carboxylate group; R2 is alkoxy group of from one to six ca...  
WO/2015/173225A1
The present invention relates to deuterated and optionally detectably labeled compounds of formula (I): R1-A-R2 and formula (V) and salts thereof, wherein Rl, R2, A, and X10-X19 have any of the values defined in the specification. Also i...  
WO/2015/173763A1
The invention relates to the new medical use of (4R)-2-(4-phenyl-2-oxopyrrolidin-1-yl)acetamide for the treatment of pathological conditions, including sepsis and peripheral neuropathy, characterized by overexpression of iNOS gene.  
WO/2015/172722A1
A 6,8-disubstituted quinoline compound having a structure represented by formula I or a pharmaceutically acceptable salt thereof, a preparation method therefor, and uses thereof in treating Alzheimer's disease. This compound has acetylch...  
WO/2015/174502A1
[Problem] To provide: packaging for a rivastigmine-containing adhesive patch having excellent rivastigmine stability over time; and an adhesive patch product and a manufacturing method therefor, said adhesive patch product being equipped...  
WO/2015/173802A1
The present invention is directed to a peptide conjugate comprising an alpha-amino protecting moiety, a peptide comprising the amino acid sequence at least 3 amino-acid long derived from the C'-terminus of PAR-1, or an active variant the...  
WO/2015/174098A1
This invention relates to 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]-ox y}methyl)piperidin-1-yl]methyl}tetrahydro-2H-pyran-4-carboxy lic acid for use in therapeutic treatment of the human body. In particular, it relates to...  
WO/2015/174534A1
The present invention provides a compound exhibiting cholinergic muscarinic M1 receptor positive allosteric modulator activity, the compound being useful as a drug for the prevention, treatment, or the like of Alzheimer's disease, schizo...  
WO/2015/175388A1
Methods of selecting a subject for treatment of amyotrophic lateral sclerosis (ALS) and methods of treatment for subjects having ALS or at risk of developing ALS are provided. The method of selecting subjects for treatment includes obtai...  
WO/2015/174532A1
 Provided is an antidepressant useful against depression. A depression treatment agent configured by containing N-acetyl-D-mannosamine, and a pharmaceutical composition for the treatment of depression configured by containing an active...  
WO/2015/173133A1
The present invention relates to a 1-phenylalkanecarboxylic acid and at least one additional neuroprotective agent for use of in a combination therapy for the prevention or therapeutic treatment of proteinopathies and/or neurodegenerativ...  
WO/2015/175898A1
The present invention includes a method for diagnosis and treatment and prevention of Alzheimer's Disease comprising obtaining a biological sample from a subject suspected of having Alzheimer's Disease; determining the level of expressio...  
WO/2015/173258A1
The present invention is directed to pharmaceutical solution comprising at least dopamine for use in treating Parkinson's disease, wherein said pharmaceutical solution is kept under anaerobic conditions from its formulation to its admini...  
WO/2015/174475A1
Provided is a composition for oral intake, having improved oral absorption of curcumin and/or an analog thereof and being capable of being easily and inexpensively produced. A complex of curcumin and/or an analog thereof and a water-solu...  
WO/2015/170122A1
The present invention relates to a CRH formulation and to a method of producing the CRH formulation, and to methods of treatment using said CRH formulation.  
WO/2015/170683A1
The objective of the present invention is to provide: an NOX inhibitor and an NFκB inhibitor, each having excellent activity; and a prophylactic or therapeutic agent for diseases associated with NOX or NFκB, which utilizes the NOX inhi...  
WO/2015/171765A2  

Matches 701 - 750 out of 111,695